BUND FINANCE › Stocks › MDT
Medtronic Plc (MDT)
NYSE · Stock price, chart and technical analysis
Data from Financial Modeling Prep · Nov 18, 2026, 4:00 PM New York time · may be delayed
Key stats
Quick technical read
- Price is +7.04% above its 50-day average.
- It is +14.12% above its 200-day average (long-term uptrend).
- It sits at 83% of its 52-week range (0% = low, 100% = high).
This describes price action; it is not a recommendation. The app also calculates RSI, MACD, the entry setup and 30+ indicators. How we calculate it
Fundamentals Annual
| Fiscal year | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Revenue | US$31.7B | US$31.2B | US$32.4B | US$33.5B | US$36.4B |
| Net income | US$5.0B | US$3.8B | US$3.7B | US$4.7B | US$4.8B |
| EPS (diluted) | 3.73 | 2.82 | 2.76 | 3.61 | 3.73 |
| Gross margin | 68.0% | 65.7% | 65.3% | 65.3% | 65.0% |
| Operating margin | 18.2% | 17.6% | 15.9% | 17.8% | 17.8% |
| Net margin | 15.9% | 12.0% | 11.4% | 13.9% | 13.2% |
| Free cash flow | US$6.0B | US$4.6B | US$5.2B | US$5.2B | US$5.4B |
| Total debt | US$24.1B | US$24.4B | US$25.0B | US$28.5B | US$28.0B |
| Cash | US$3.7B | US$1.5B | US$1.3B | US$2.2B | US$1.9B |
Compound annual growth: revenue 3.5% · net income -1.2% (4 years).
Valuation: today, its history and its sector
| Today | 5-year average | Sector median (Healthcare) | |
|---|---|---|---|
| P/E | 24.8x | 26.8x | 27.1x |
| EV / EBITDA | 14.6x | 15.8x | 16.5x |
| Operating margin | 18.1% | — | 3.6% |
| Net margin | 13.9% | — | -0.0% |
| Debt / equity | 0.85 | — | 0.58 |
Source: annual financial statements from Financial Modeling Prep. “Today” uses the current price and the last 4 quarters. The sector median uses U.S. companies above US$300M market cap. A multiple above or below its history or sector is not a recommendation.
About Medtronic Plc
Medtronic plc is a leading global medical technology enterprise that invents, develops, manufactures, and distributes an extensive range of device-based medical therapies. These solutions serve healthcare systems, clinicians, physicians, and patients across the world. The company's operations are categorized into several key portfolios: Cardiovascular Portfolio: This segment focuses on cardiac health, providing technologies for heart rhythm management, including implantable pacemakers, defibrillators, and monitoring systems, alongside cardiac ablation tools and remote patient software. It also addresses structural heart issues with products like aortic and pulmonary valves, surgical repair d…
Other stocks on BUND FINANCE
Not financial advice. BUND FINANCE publishes general information for educational purposes. Investing involves risk, including loss of capital. Legal notice